GeoMETry-C: Study of Capmatinib in Chinese Adult Patients With Advanced Non-small Cell Lung Cancer Harboring MET Exon 14 Skipping Mutation

Sponsor

Novartis Pharmaceuticals (Industry)

Overall Status

Recruiting

CT.gov ID

NCT04677595

Collaborator

(none)

Enrollment

Locations

Arms

32.2

Anticipated Duration (Months)

1.8

Patients Per Site

0.1

Patients Per Site Per Month

Study Details

Study Description

Brief Summary

The purpose of the study is to learn whether the study treatment (capmatinib), which already shows efficacy and safety in non-Chinese patients, could help Chinese patients with controlling their lung cancer in a safe way. Participants will have a type of lung cancer called non-small cell lung lancer (NSCLC), with a specific alteration in a part of their DNA (called mutation) of the MET gene, within a specific part of this gene called exon 14.

Participants who have advanced (or metastatic) non-small cell lung cancer with specific mutations in the MET gene but without mutations in the EGFR or ALK genes, who are aged 18 years or older will be enrolled in this study.

The study drug, capmatinib (also known as INC280), is an oral drug that is called a 'targeted' medicine, which means it targets particular processes that may not be working properly in cancer cells (called dysregulation). The dysregulation of the MET signaling in cancer cells of patients with NSCLC is believed to make the cancer worse. Capmatinib has been shown to selectively block the effects of the MET gene and therefore may help in keeping the disease under control, stopping cancer cells from growing.

Condition or Disease	Intervention/Treatment	Phase
Non-Small Cell Lung Cancer (NSCLC)	Drug: Capmatinib	Phase 2

Detailed Description

This is an open-label, multicenter two-cohort phase II study. Chinese adult participants with EGFR wild-type (wt) (EGFR mutations that predict sensitivity to EGFR therapy, including, but not limited to exon 19 deletions and exon 21 L858R substitution mutations), anaplastic lymphoma kinase (ALK) rearrangement negative, advanced (stage IIIB, IIIC or IV) NSCLC disease harboring MET exon 14-skipping (METΔex14) mutations as determined by a Novartis central molecular laboratory will be treated in this study. Cohort 1 will include treatment naive participants and Cohort 2 participants who failed one or two prior lines of therapy in the advanced stage (stage IIIB, IIIC or IV). Each participant will receive 400 mg capmatinib tablet twice daily (BID).

The primary endpoint is the overall response rate (ORR) by cohort as per the blinded independent review committee (BIRC) review. ORR is defined as the proportion of participants with best overall response (BOR) of complete response (CR) or partial response (PR) according to RECIST 1.1.

The primary analysis will be performed using full analysis set (FAS). The primary efficacy endpoint ORR will be estimated and the exact 95% confidence interval (CI) will be provided by cohort.

Study Design

Study Type:

Interventional

Anticipated Enrollment :

35 participants

Allocation:

Non-Randomized

Intervention Model:

Single Group Assignment

Masking:

None (Open Label)

Primary Purpose:

Treatment

Official Title:

A Phase II, Multicenter, Two-cohort Study of Oral MET Inhibitor Capmatinib in Chinese Adult Patients With EGFR Wild-type (wt), ALK Rearrangement Negative, MET Exon 14 Skipping Mutations, Advanced Non-small Cell Lung Cancer (NSCLC) Who Are Treatment Naive or Failed One or Two Prior Lines of Systemic Therapy

Actual Study Start Date :

May 17, 2021

Anticipated Primary Completion Date :

Dec 12, 2023

Anticipated Study Completion Date :

Jan 23, 2024

Arms and Interventions

Arm	Intervention/Treatment
Experimental: Cohort 1 Treatment Naive participants	Drug: Capmatinib 400 mg of capmatinib tablets, administered orally twice daily Other Names: INC280
Experimental: Cohort 2 Participants received one or two prior lines of treatment	Drug: Capmatinib 400 mg of capmatinib tablets, administered orally twice daily Other Names: INC280

Arm

Intervention/Treatment

Experimental: Cohort 1

Treatment Naive participants

Drug: Capmatinib

400 mg of capmatinib tablets, administered orally twice daily

Other Names:

INC280

Experimental: Cohort 2

Participants received one or two prior lines of treatment

Drug: Capmatinib

400 mg of capmatinib tablets, administered orally twice daily

Other Names:

INC280

Outcome Measures

Primary Outcome Measures

Overall response rate (ORR) by blinded independent review committee (BIRC) assessment, by cohort [Up to approximately 23 months]
ORR is defined as the proportion of participants with a best overall response (BOR) defined as complete response or partial response (CR+PR) by BIRC assessment per RECIST 1.1

Secondary Outcome Measures

Duration of response (DOR) as assessed by BIRC, by cohort [From first documented response to first documented progression or death due to any cause, whichever comes first, assessed up to approximately 23 months]
DOR, calculated as the time from the date of the first documented CR or PR by BIRC per RECIST 1.1 to the first documented progression or death due to any cause for participants with PR or CR
Overall response rate (ORR) and duration of response (DOR) by investigator assessment, by cohort [Up to approximately 23 months]
ORR (CR+PR) and DOR per RECIST 1.1 by investigator assessment
Time to response (TTR) by investigator and by BIRC assessment, by cohort [From first dose to first documented response of either CR or PR, assessed up to approximately 23 months]
TTR, calculated as the time from first dose of capmatinib to first documented response (CR+PR) for participants with PR or CR per RECIST 1.1 by BIRC and investigator
Disease Control Rate (DCR) by investigator and by BIRC assessment, by cohort [Up to approximately 23 months]
DCR, calculated as the proportion of participants with BOR of CR, PR, or SD (stable disease) per RECIST 1.1 by BIRC and investigator
Progression Free Survival (PFS) by investigator and by BIRC assessment, by cohort [From first dose to the date of first documented progression or death from any cause, whichever comes first, assessed up to approximately 23 months]
PFS, defined as time from first dose of capmatinib to progression or death due to any cause per RECIST 1.1 by BIRC and investigator
Overall survival (OS) [From first dose to death due to any cause, assessed up to approximately 42 months]
OS is defined as the time from first dose to the date of death due to any cause.
Overall intracranial response rate (OIRR) [Up to approximately 23 months]
Overall intracranial response rate (OIRR) calculated as the proportion of participants with a confirmed best overall intracranial response (BOIR) of CR or PR per Response Assessment in Neuro-Oncology Brain Metastases (RANO-BM) criteria as assessed by BIRC
Intracranial disease control rate (IDCR) [Up to approximately 23 months]
Intracranial disease control rate (IDCR), defined as the proportion of participants with a confirmed BOIR of CR or PR or SD (or non-CR/non-Progressive Disease) per RANO-BM criteria as assessed by BIRC review.
Time to intracranial response (TTIR) [Up to approximately 23 months]
Time to intracranial response (TTIR) defined as the time from the date of the start of study treatment to the date of the first documented intracranial response of either CR or PR per RANO-BM criteria as assessed by BIRC
Duration of intracranial response (DOIR) [Up to approximately 23 months]
Duration of intracranial response (DOIR) defined as the time from the date of first documented intracranial response of either CR or PR to the date of the first documented intracranial progression per RANO-BM criteria as assessed by BIRC review or date of death due to any cause.
Association between MET mutation status as measured in ctDNA at baseline with capmatinib efficacy [Up to approximately 23 months]
ORR, DOR and PFS per RECIST 1.1 for participants by MET mutation status assessed in circulating tumor DNA (ctDNA) at baseline, both by BIRC and investigator. The association between MET mutation status as measured in ctDNA at baseline with ORR, DOR and PFS will be established using Kaplan-Meier curve by cohort separately. Median survival together with their 95% confidence intervals will be reported.
Plasma capmatinib concentration [Cycle 2 Day 1 pre-dose, 0.5-1.5 hours post-dose and 3-5 hours post dose and Cycle 3 Day 1 pre-dose. Each cycle duration is 21 days]
Steady state Ctrough and steady state 0.5- 1.5 hour and 3-5 hours post-dose concentrations
Change from baseline in score as per European Organization for Research and Treatment of Cancer (EORTC) Quality of Life Questionnaire (QLQ)-C30 [Cycle 1 Day 1, Cycle 3 Day 1 and then every 6 weeks up to approximately 23 months. Each cycle duration is 21 days.]
EORTC-QLQ-C30 is a 30-item questionnaire developed to assess the quality of life of cancer patients.
Change from baseline in score as per European Organization for Research and Treatment of Cancer (EORTC) Quality of Life Lung Cancer Module (QLQ-LC13) [Cycle 1 Day 1, Cycle 3 Day 1 and then every 6 weeks up to approximately 23 months. Each cycle duration is 21 days.]
EORTC QLQ-LC13 is a 13-item lung cancer specific questionnaire.
Change from baseline in score as per European Quality of Life 5-Dimension 5-Level (EQ-5D-5L) questionnaire [Cycle 1 Day 1, Cycle 3 Day 1 and then every 6 weeks up to approximately 23 months. Each cycle duration is 21 days.]
EQ-5D-5L is a standardized measure to assess the overall health-related quality of life in patients.
Time to deterioration in symptoms of brain metastases, with the NCCN FACT-Brain Symptom Index symptom module (FBrSI) [Cycle 1 Day 1, Cycle 3 Day 1 and then every 6 weeks up to approximately 23 months. Each cycle duration is 21 days.]
National Comprehensive Cancer Network Functional Assessment of Cancer Therapy (NCCN FACT) - Brain Symptom Index version 2.0 (FBrSI) symptom module, consisting of 24 items with a recall period of the past 7 days, will explore changes in symptoms associated with potential brain metastases.

Eligibility Criteria

Criteria

Ages Eligible for Study:

18 Years and Older

Sexes Eligible for Study:

All

Accepts Healthy Volunteers:

Key Inclusion Criteria:

Chinese adult ≥ 18 years old at the time of informed consent
Histologically confirmed stage IIIB, IIIC or IV NSCLC at the time of study entry, not amenable to curative surgery or radiation or multi-modality therapy (according to staging definition in CSCO guidelines for primary lung cancer, 2019).
Histologically or cytologically confirmed diagnosis of NSCLC that is:

EGFR wt: The EGFR wt status assessed as part of standard of care (EGFR mutations that predict sensitivity to EGFR therapy, including, but not limited to exon 19 deletions and exon 21 L858R substitution mutations)
AND ALK rearrangement negative: assessed as part of standard of care by validated test
AND either:

Cohort 1: Treatment naive participants with MET mutations, or Cohort 2: Pre-treated participants with MET mutations

Cohort 1: participants must not have received any systemic therapy for advanced/metastatic disease (stage IIIB, IIIC or IV NSCLC). Neo-adjuvant and adjuvant systemic therapies will not count as one prior line of treatment if relapse occurred > 12 months from the end of the neo-adjuvant or adjuvant systemic therapy.
Cohort 2: participants must have failed one or two prior lines of systemic therapy for advanced/metastatic disease (stage IIIB, IIIC or IV NSCLC).
At least one measurable lesion according to RECIST v1.1.
Adequate organ function
ECOG performance status (PS) ≤1

Key Exclusion Criteria:

Prior treatment with any MET inhibitor or HGF-targeting therapy.
Known druggable molecular alterations (such as ROS1 translocation or BRAF mutation, etc.) which might be a candidate for alternative targeted therapies as applicable per local regulations and treatment guidelines.
Participants with symptomatic central nervous system (CNS) metastases who are neurologically unstable or have required increasing doses of steroids within the 2 weeks prior to study entry to manage CNS symptoms.
Presence or history of interstitial lung disease or interstitial pneumonitis, including, clinically significant radiation pneumonitis affecting activities of daily living or requiring therapeutic intervention.
Substance abuse, active infection (including active hepatitis B and C, participants whose disease is controlled under antiviral therapy are eligible, and human immunodeficiency virus (HIV) history positive) or other severe, acute, or chronic medical or psychotic conditions or laboratory abnormalities that in the opinion of the investigator may increase the risk associated with study participation, or that may interfere with the interpretation of study results.

Other protocol-defined inclusion/exclusion criteria may apply.

Contacts and Locations

Locations

	Site	City	State	Country	Postal Code
1	Novartis Investigative Site	Xiamen	Fujian	China	361001
2	Novartis Investigative Site	Foshan	Guangdong	China	528000
3	Novartis Investigative Site	Guangzhou	Guangdong	China	51000
4	Novartis Investigative Site	Guangzhou	Guangdong	China	510515
5	Novartis Investigative Site	Zhanjing	Guangong	China	524000
6	Novartis Investigative Site	Harbin	Heilongjiang	China	150081
7	Novartis Investigative Site	Zhengzhou	Henan	China	450003
8	Novartis Investigative Site	Wuhan	Hubei	China	430022
9	Novartis Investigative Site	Changsha	Hunan	China	410013
10	Novartis Investigative Site	Shenyang	Liaoning	China	110011
11	Novartis Investigative Site	Jinan	Shandong	China	250117
12	Novartis Investigative Site	Shanghai	Shanghai	China	200032
13	Novartis Investigative Site	Shanghai	Shanghai	China	200433
14	Novartis Investigative Site	Chengdu	Sichuan	China	610041
15	Novartis Investigative Site	Urumchi	Xinjiang	China	830000
16	Novartis Investigative Site	Kunming	Yunnan	China	650106
17	Novartis Investigative Site	Hangzhou	Zhejiang	China	310022
18	Novartis Investigative Site	Beijing		China	100036
19	Novartis Investigative Site	Tianjin		China	300052